Molecular Templates, Inc.MTEM
| Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|
| Net loss | - | - | - | - | - | - | - | - | - | - | - | - | -8 |
|---|
| Depreciation, amortization and other | 5 | - | - | - | - | - | - | 1 | 1 | 4 | 7 | 7 | 7 |
|---|
| Loss on disposal of property and equipment | 0 | - | 0 | - | - | - | - | - | - | - | -0 | -0 | -0 |
|---|
| Change in valuation of contingent value right | - | - | - | - | - | - | - | - | - | - | - | - | -2 |
|---|
| Share Based Compensation | 40 | 3 | 5 | 5 | 7 | 3 | 2 | 4 | 6 | 12 | 17 | 12 | 7 |
|---|
| Amortization Of Debt Discount Premium | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
|---|
| Impairment of fixed assets and intangibles | - | - | - | - | - | - | - | - | - | - | - | 0 | - |
|---|
| Gain on extinguishment of debt | - | - | - | - | - | - | - | -0 | - | -1 | - | - | 2 |
|---|
| Accretion of asset retirement obligations | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Prepaid expenses | - | - | - | - | - | - | 0 | 1 | 0 | 4 | -0 | -0 | -1 |
|---|
| Grants revenue receivable | - | - | - | - | - | - | - | - | 3 | -7 | - | - | 0 |
|---|
| Other assets | - | - | - | - | - | - | 0 | 0 | 0 | -2 | 0 | 0 | -1 |
|---|
| Operating lease right-of-use assets and liabilities | - | - | - | - | - | - | - | - | 3 | -0 | 0 | -1 | -0 |
|---|
| Accounts payable | 2 | -1 | 1 | 0 | -1 | 0 | 1 | -2 | 1 | 0 | -1 | -1 | 1 |
|---|
| Accrued liabilities | 2 | 1 | 1 | 0 | 0 | -2 | 0 | 3 | 7 | -3 | -3 | -1 | -4 |
|---|
| Deferred revenue | - | 62 | 30 | -15 | -77 | - | 1 | - | - | - | - | - | -42 |
|---|
| Net cash used in operating activities | -24 | 30 | 10 | - | - | - | - | -4 | -25 | -84 | -30 | -89 | -42 |
|---|
| Purchases of property and equipment | 6 | 0 | 0 | 0 | 0 | - | 1 | 6 | 10 | 7 | 4 | 3 | 0 |
|---|
| Proceeds from sale of equipment | - | - | - | - | - | - | - | - | - | 0 | - | - | 0 |
|---|
| Purchase of marketable securities | 224 | 94 | 102 | - | - | - | - | 10 | 90 | 133 | 211 | 56 | 2 |
|---|
| Sales of marketable securities | 209 | 48 | - | - | - | - | - | - | 60 | 106 | 153 | 154 | 31 |
|---|
| Net cash provided by investing activities | -9 | -47 | -16 | - | - | - | - | -16 | -40 | -35 | -62 | 95 | 29 |
|---|
| Net Proceeds From Issuance Of Private Placement | - | - | - | - | - | - | - | - | - | - | - | - | 18 |
|---|
| Repayment of long-term debt | - | - | - | - | - | - | 2 | 4 | - | 5 | - | - | 28 |
|---|
| Proceeds from stock option exercises | - | - | - | - | - | - | 0 | 0 | 2 | 1 | 2 | 0 | 0 |
|---|
| Fees paid on loan modification | - | - | - | - | - | - | - | - | - | - | - | 0 | - |
|---|
| Net cash used in financing activities | 232 | 22 | 2 | - | - | - | - | 49 | 66 | 59 | 93 | -0 | -9 |
|---|
| Net (decrease)/increase in cash, cash equivalents, and restricted cash | - | - | - | - | - | - | - | - | 1 | -60 | -0 | 6 | -22 |
|---|
| Interest Paid Net | - | - | - | - | - | - | 0 | 1 | 1 | 1 | 2 | 3 | 2 |
|---|
| Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | - | - | - | - | - | - | - | - | - | - | - | 5 | - |
|---|
| Fixed asset additions in accounts payable and accrued expenses | - | - | - | - | - | - | - | - | 3 | 1 | 0 | 0 | - |
|---|